Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats

Brain Research

Volumn 994, Issue 2, 2003, Pages 188-192

  Andreassen, Ole A ^a   Waage, Jo ^b   Finsen, Bente ^c   Jørgensen, Hugo A ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antipsychotics; In situ hybridization; Stereology; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; MEMANTINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL ASSAY; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FEMALE; MASTICATION; MEASUREMENT; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TARDIVE DYSKINESIA;

EID: 0344430059     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.09.035     Document Type: Article

References (28)

1. Andreassen O.A., Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61:2000;525-541.
2. Andreassen O.A., Aamo T.O., Jørgensen H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmacol. 119:1996;751-757.
3. Andreassen O.A., Finsen B., Østergaard K., Sørensen J.C., West M.J., Jørgensen H.A. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Neuroscience. 88:1999;27-35.
4. Andreassen O.A., Meshul C.K., Moore C., Jørgensen H.A. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacology (Berl.). 157:2001;11-19.
5. Angulo J.A. Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem. 58:1992;1104-1109.
6. Auchus A.P., Pickel V.M. Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp. Neurol. 117:1992;17-27.
7. Bauer R., Mayr A., Lederer W., Needham P.L., Kilpatrick I.C., Fleischhacker W.W., Marksteiner J. Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs. Neuropsychopharmacology. 23:2000;46-55.
8. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., Parker W.D. Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33:1993;512-517.
9. Delfs J.M., Yu L., Ellison G.D., Reisine T., Chesselet M.F. Regulation of mu-opioid receptor mRNA in rat globus pallidus: effects of enkephalin increases induced by short- and long-term haloperidol administration. J. Neurochem. 63:1994;777-780.
10. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., Kleinman J.E. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
11. Goff D.C., Tsai G., Beal M.F., Coyle J.T. Tardive dyskinesia and substrates of energy metabolism in CSF. Am. J. Psychiatry. 152:1995;1730-1736.
12. Gunne L.M., Haggstrom J.E., Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 309:1984;347-349.
13. Hong J.S., Yang H.Y., Gillin J.C., Di Giulio A.M., Fratta W., Costa E. Chronic treatment with haloperidol accelerates the biosynthesis of enkephalins in rat striatum. Brain Res. 160:1979;192-195.
14. Jeste D.V., Caligiuri M.P. Tardive dyskinesia. Schizophr. Bull. 19:1993;303-315.
15. Liminga U., Johansson P., Nylander I., Gunne L.M. Intranigral infusion of enkephalins elicits dyskinetic biting in rats. Psychopharmacology (Berl.). 99:1989;299-303.
16. McCormick S.E., Stoessl A.J. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience. 112:2002;851-859.
17. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 34:1993;713-738.
18. Mion C.C., Andreasen N.C., Arndt S., Swayze V.W. II, Cohen G.A. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 40:1991;157-166.
19. Moghaddam B., Bunney B.S. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 14:1993;195-200.
20. Pall H.S., Williams A.C., Blake D.R., Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet. 2:1987;596-599.
21. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
22. Petersen R., Finsen B., Andreassen O.A., Zimmer J., Jørgensen H.A. No changes in dopamine D1 receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol treatment. Brain Res. 859:2000;394-397.
23. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348:2003;1333-1341.
24. Sakai K., Gao X.M., Tamminga C.A. Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats. Psychopharmacology (Berl.). 153:2001;191-195.
25. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 155:1998;1207-1213.
26. West M.J., Østergaard K., Andreassen O.A., Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J. Comp. Neurol. 370:1996;11-22.
27. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.
28. Zhang F., Van Bree L., Albala N., Verslype M., Vanderhaeghen J.J. NMDA receptor antagonist MK-801 down-regulates rat striatal proenkephalin and protachykinin mRNAs. Neurochem. Int. 28:1996;189-192.